Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver Metastases

PHASE1RecruitingINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

May 13, 2025

Primary Completion Date

December 30, 2025

Study Completion Date

June 1, 2026

Conditions
Colorectal Liver MetastasesFirst-line Treatment
Interventions
DRUG

paclitaxel cationic liposome for injection

Paclitaxel cationic liposome was administered through hepatic arterial catheter infusion, in a gradual increment dose range from 33 mg/m\^2 to 55 mg/m\^2

DRUG

Oxaliplatin

Oxaliplatin 130 mg/m2 i.v. on D1

DRUG

Capecitabine

Capecitabine 1000 mg/m2 p.o. Bid on Day 1-14

DRUG

Bevacizumab

Bevacizumab 7.5 mg/kg i.v. on D1

Trial Locations (1)

Unknown

RECRUITING

The First Affiliated Hospital of Sun Yat-sen University,Lishui Central Hospital, Lishui

All Listed Sponsors
lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY

NCT07117435 - Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver Metastases | Biotech Hunter | Biotech Hunter